ClinicalTrials.Veeva

Menu

Antibiotic Prophylaxis for Endoscopic Ultrasound Guided Fine Needle Aspiration of Pancreatic Cystic Lesions

F

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Status and phase

Completed
Phase 4

Conditions

Pancreatic Cystic Lesion

Treatments

Drug: Placebo
Drug: Ciprofloxacin

Study type

Interventional

Funder types

Other
NETWORK

Identifiers

NCT02261896
IIBSP-CIP-2013-166

Details and patient eligibility

About

The purpose of this study is to determine whether the use of antibiotic prophylaxis is appropriate when performing a pancreatic cyst fine needle aspiration guided by endoscopic ultrasonography.

Full description

The incidence of infection after a pancreatic cyst fine needle aspiration guided by endoscopic ultrasonography (EUS-FNA) is not well known. Antibiotic prophylaxis is recommended in clinical guidelines despite the lack of evidence of its usefulness.

Our hypothesis is that the risk of infection will not be higher with placebo, and risks associated to the use of antibiotics might even increase with the use of prophylaxis.

The main objective of the project is to assess the risk of infection after the procedure and to determine whether the use of antibiotic prophylaxis is appropriate. The study is a phase IV, multicenter, double-blinded, randomized, placebo-controlled, and non-inferiority trial . We have designed a study with two parallel treatment groups. Patients will be randomized to the prophylaxis or to the placebo group. All patients will be followed for 21 days or until resolution of complications. To evaluate this primary objective with a non inferiority study, we have estimated that a total of 218 patients will be needed (109 per group) .

The main secondary objective is to assess the incidence of complications related to the use of antibiotic prophylaxis (i.e. allergic reactions, secondary infections or drug-resistant infections).

Enrollment

226 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with a pancreatic cyst requiring EUS-FNA to complete evaluation.
  • Participant is willing and able to give informed consent for participation in the study.
  • Age 18 years or older.
  • Ability to understand study procedures and to comply with them for the entire length of the study.

Exclusion criteria

  • Patients with other co-morbidities requiring antibiotic prophylaxis for endoscopic invasive procedures (such as those with cardiac valve prosthesis).
  • Cystic lesion of the intestinal wall (foregut or duplication cyst).
  • Use of antibiotic treatment for any other indication during the 5 days prior to the procedure.
  • Pregnant woman.
  • Known allergy/sensitivity to ciprofloxacin.
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

226 participants in 2 patient groups

Placebo
Experimental group
Description:
1 intravenous dose followed by 1 oral dose each 12 hours (complete 3 days)
Treatment:
Drug: Placebo
Antibiotic
Active Comparator group
Description:
Ciprofloxacin 400 mg intravenous one dose followed by ciprofloxacin 500 mg oral each 12 hours (complete 3 days)
Treatment:
Drug: Ciprofloxacin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems